LAVA Therapeutics NVNASDAQ:LVTX
- LAST PRICE1.6000
- TODAY'S CHANGE (%)0.1200 (8.1081%)
- Bid / Lots1.4800/ 5
- Ask / Lots1.9100/ 2
- Open / Previous Close1.5000 / 1.4800
- Day Range
- 52 Week Range
- Volume30,152
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | LVTX |
|---|---|---|
| 09:32 ET | 898 | 1.48 |
| 09:35 ET | 1000 | 1.5063 |
| 09:53 ET | 5213 | 1.54 |
| 10:06 ET | 100 | 1.53 |
| 10:13 ET | 800 | 1.54 |
| 10:15 ET | 6200 | 1.5499 |
| 10:20 ET | 100 | 1.53 |
| 10:27 ET | 700 | 1.55 |
| 10:38 ET | 2200 | 1.54 |
| 10:47 ET | 3958 | 1.56 |
| 11:07 ET | 100 | 1.58 |
| 11:09 ET | 2223 | 1.595 |
| 11:12 ET | 100 | 1.62 |
| 11:16 ET | 100 | 1.602 |
| 11:32 ET | 313 | 1.58 |
| 11:36 ET | 200 | 1.59 |
| 11:50 ET | 1500 | 1.63 |
| 11:52 ET | 100 | 1.63 |
| 12:03 ET | 500 | 1.63 |
| 12:35 ET | 400 | 1.582 |
| 01:22 ET | 400 | 1.59 |
| 01:26 ET | 100 | 1.62 |
| 01:40 ET | 200 | 1.58 |
| 02:09 ET | 100 | 1.5823 |
| 02:52 ET | 100 | 1.6 |
| 03:24 ET | 200 | 1.6 |
| 03:48 ET | 100 | 1.66 |
| 03:50 ET | 100 | 1.6 |
| 03:55 ET | 100 | 1.64 |
| 04:00 ET | 616 | 1.6 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
LAVA Therapeutics NV | 38.9M | -1.8x | --- |
Tonix Pharmaceuticals Holding Corp | 38.2M | 0.0x | --- |
BioLine RX Ltd | 34.4M | -0.4x | --- |
Kronos Bio Inc | 52.7M | -0.6x | --- |
Affimed NV | 40.2M | -0.5x | --- |
Pulmatrix Inc | 22.3M | -2.3x | --- |
Company Information
LAVA Therapeutics NV, formerly known as Lava Therapeutics BV, is a provider of biotechnology research and development services based in the Netherlands. The Company focuses of developing next generation Vdelta T cell engaging bispecific antibodies to fight cancer.
Contact Information
- Headquarters
- Yalelaan 60UTRECHT, Netherlands 3584 CM
- Phone
- ---
- Fax
- ---
Executives
- Non-Executive Chairman of the Board
- Kapil Dhingra
- President, Chief Executive Officer, Management Director
- Stephen Hurly
- Chief Financial Officer
- Edward Smith
- Executive Vice President Head of Research and Development
- Paul Parren
- Chief Scientific Officer
- Hans Van Der Vliet
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $38.9M |
|---|---|
Revenue (TTM) | $7.4M |
Shares Outstanding | 26.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.43 |
EPS | $-0.90 |
Book Value | $1.95 |
P/E Ratio | -1.8x |
Price/Sales (TTM) | 5.3 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -371.48% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
